OrganoTherapeutics

What OrganoTherapeutics does

OrganoTherapeutics SARL is a Luxembourg-based biotechnology company spun out in July 2019 from the University of Luxembourg\u2019s Luxembourg Centre for Systems Biomedicine (LCSB). It specializes in human iPSC-derived brain organoid and assembloid models \u2014 including midbrain, microglia-containing, vascular, hindbrain, and striatum organoids and their assembloid combinations \u2014 applied primarily to Parkinson\u2019s disease drug discovery and translational neuroscience. Its core technical platform combines patient-derived cell biology with image-based phenotyping and a multi-modal Parkinson\u2019s Disease Knowledge Graph (PD-KG) intended to integrate data across organoid projects and accelerate target identification.

The company operates a B2B research services model, selling project-based engagements of typically 3\u20139 months duration directly via email and its website. Customer segments span pharmaceutical and biotechnology companies developing CNS therapeutics, academic and clinical research institutions, and rare neurological disease patient advocacy groups. Named collaborators include Priavoid GmbH, the Michael J. Fox Foundation (LITE program, from April 2025), StressMarq Biosciences, and CASK Luxembourg asbl (MOU signed March 2026). Capital support includes a 2023 investment from European life sciences fund KHAN-I, and operations were expanded in December 2024 with a move to the House of Biohealth in Luxembourg. The company holds granted US patent US11976296B2 covering disease-specific midbrain organoid compositions and uses.

Name

OrganoTherapeutics

Legal name

OrganoTherapeutics SARL

Website

https://organo-therapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

OrganoTherapeutics is a Luxembourg-based biotech spun out of the University of Luxembourg in 2019 that develops iPSC-derived brain organoid and assembloid models to support Parkinson\u2019s disease drug discovery for pharma, academic, and rare disease clients.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Services

NAICS

Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

Keywords

• Brain organoid models
• Parkinson's disease research
• IPSC-derived organoids
• Drug discovery services
• Neuroscience preclinical research

Headquarters

HQ city

Esch-sur-alzette

HQ country

Luxembourg

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Services and Custom Projects: OrganoTherapeutics offers tailored research projects and services from experiments to data analysis and interpretation. Projects include project design, organoid generation, compound treatment, experimental analysis, and data analysis. Pricing depends entirely on the project scope, number of cell lines, conditions, and assay readouts. Typical projects last from 3 to 9 months.
2. Organoid Products: Sale of iPSC-derived human organoid and assembloid products including midbrain organoids, microglia-containing midbrain organoids, vascular-midbrain assembloids, hindbrain organoids, hindbrain-midbrain assembloids, striatum organoids, and midbrain-striatum assembloids. Products are ordered by contacting the company directly.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

OrganoTherapeutics provides tailored preclinical research services using iPSC-derived human brain organoid and assembloid systems, with a primary focus on Parkinson's Disease. The company sells organoid products (midbrain, microglia-containing, vascular, hindbrain, striatum, and assembloid variants) and offers custom research projects spanning project design, organoid generation, compound treatment, experimental analysis, and data interpretation. It also operates the PD Knowledge Graph for multi-modal data integration.

Product overview

OrganoTherapeutics offers a portfolio of iPSC-derived human brain organoid and assembloid systems for Parkinson's Disease research and drug discovery. The product line includes specialized midbrain organoids (rich in dopaminergic neurons), microglia-containing midbrain organoids, vascular-midbrain assembloids, hindbrain organoids, hindbrain-midbrain assembloids, striatum organoids, and midbrain-striatum assembloids. These models are complemented by tailored research services spanning experimental design, organoid generation, compound treatment, experimental analysis, and data interpretation. The company also provides a PD Knowledge Graph (PD-KG) for multi-modal data integration. Advanced capabilities include AI-assisted image analysis for deep phenotyping.

Differentiator

Problem solved

Functional benefit

Products and services

• Midbrain Organoids 3D iPSC-derived organoid models of the human midbrain, rich in dopaminergic neurons, designed for Parkinson's Disease modeling and drug screening. Sold to pharmaceutical, biotech, and academic researchers.
• Microglia-Containing Midbrain Organoids Midbrain organoids enriched with microglia to model neuroinflammatory responses in Parkinson's Disease. Sold to neuroscience and drug discovery researchers.
• Vascular-Midbrain Assembloids Midbrain organoids co-cultured with vascular assembloids to integrate a vascular network within the tissue for more physiologically relevant disease modeling. Sold to neuroscience researchers.
• Hindbrain Organoids Organoid models of the human hindbrain, used in combination with other brain region organoids to study protein spread such as alpha-synuclein pathology. Sold to neuroscience researchers.
• Hindbrain-Midbrain Assembloids Co-culture of hindbrain and midbrain organoids used to study alpha-synuclein spread and other pathological mechanisms across brain regions. Sold to neuroscience researchers.
• Striatum Organoids Organoid models of the human striatum for studying neurodegeneration in Parkinson's Disease and related basal ganglia disorders. Sold to neuroscience researchers.
• Midbrain-Striatum Assembloids Midbrain and striatum organoids co-cultured to model the nigrostriatal pathway, ideal for studying the selective degeneration of dopaminergic neurons characteristic of Parkinson's Disease. Sold to neuroscience researchers.
• Tailored Research Projects and Services Customizable preclinical research services including project design, organoid generation, compound treatment, experimental analysis (neuronal phenotypes, autophagy, mitochondrial phenotypes, neuroinflammation), and comprehensive data analysis with interpretation. Sold to pharmaceutical companies, biotech firms, and academic researchers, with typical project durations of 3 to 9 months.
• PD Knowledge Graph (PD-KG) Multi-modal data integration platform combining high-content imaging results and RNA-seq data with information from public databases to enable patient stratification and identification of altered genes across different Parkinson's Disease forms. Available to research collaborators and partners.

Quantifiable outcome

• Demonstrated reproducibility of PD patient-specific midbrain organoid data across batches and time points (GBA-N370S mutation models)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered strategic, flagship and minor.

• CASK Luxembourg asblstrategicStrategic or Co-development Partner · 31 March 2026Memorandum of Understanding signed to develop patient-derived brain organoid models for CASK, a rare X-linked neurodevelopmental disorder. Partnership combines OrganoTherapeutics' organoid expertise with CASK Luxembourg asbl's community resources to create robust models for understanding CASK biology and accelerating therapeutic strategies. CASK Luxembourg asbl has launched a fundraising campaign to advance the project.
• Priavoid GmbHstrategicStrategic or Co-development Partner · 20 March 2026Collaboration on PRI-101, an innovative all-D-peptide therapeutic demonstrating ability to actively disassemble α-synuclein aggregates. OrganoTherapeutics contributed organoid platforms showing reductions in pathological α-synuclein species accompanied by measurable functional improvements, validating PRI-101's preclinical proof-of-concept at AD/PD 2026.
• molmirstrategicStrategic or Co-development Partner · 1 July 2025Strategic collaboration with Japanese deep-tech startup pioneering molecular dynamics detection technologies. Partnership combines OrganoTherapeutics' midbrain organoid models with molmir's CHEmir and MAGmir technologies utilizing analytical chemistry and solution NMR to evaluate molecular kinetics for accelerating Parkinson's disease therapeutics development. Initial focus on a joint R&D project funded under a European innovation framework.
• Michael J. Fox Foundation - LRRK2 Therapeutics Exchange (LITE)flagshipStrategic or Co-development Partner · 24 April 2025OrganoTherapeutics joined the LITE program bringing together biotech innovators, academic researchers, and drug developers to accelerate therapeutic progress for LRRK2-associated Parkinson's disease. The Exchange focuses on sharing data, making tools and models more accessible, and enabling faster evaluation of candidate compounds. OrganoTherapeutics contributes midbrain organoid models for studying PD pathology in a human-like context.
• Animal Free Research UKminorStrategic or Co-development Partner · 12 March 2025Project collaboration to advance innovative, animal-free research methods. OrganoTherapeutics cultured human iPSC-derived midbrain organoids using various animal-free extracellular matrices and evaluated recombinant antibodies as animal-free alternatives. Findings reinforced the potential of animal-free research methodologies in biomedical science.
• mo:restrategicTechnology or Integration · 25 January 2024Partnership for organoid culture automation. mo:re provides cutting-edge automation and AI-assisted robotic and software platform integrated with OrganoTherapeutics' organoids. This collaboration enhances research capabilities and accelerates breakthroughs in therapeutic development by enabling large-scale organoid production.
• Autonomous University of Barcelona (UAB)strategicStrategic or Co-development Partner · 18 January 2024Collaboration with Professor Salvador Ventura's Protein Folding and Conformational Disorders' group for joint development of new therapeutics against Parkinson's disease. UAB and OT will jointly further develop candidate molecules initially developed in the Ventura lab targeting protein structure, function and aggregation in neurodegenerative diseases.
• Juntendo UniversitystrategicStrategic or Co-development Partner · 30 November 2023Partnership for the transfer of PD patient samples and stem cell lines. Juntendo University in Tokyo provides OrganoTherapeutics with various stem cell lines generated at their institution, including lines from different individuals with PD-associated mutations and different genetic backgrounds. This broadens the foundation for patient-specific brain organoid models and accelerates therapeutics development.
• StressMarq Biosciences Inc.strategicTechnology or Integration · 26 October 2023Collaboration focused on advancing research on Parkinson's Disease alpha-synuclein pathology in midbrain organoids. The partnership establishes an RT-QuIC assay for alpha-synuclein amplification in organoid models using StressMarq's products and expertise. This assay enables detection of pathological alpha-synuclein aggregates in samples and serves as a primary readout in drug screenings.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Others

• StressMarq Biosciences: Canada-based supplier of neurodegenerative disease research reagents including alpha-synuclein proteins and RT-QuIC assay components. Ecosystem partner supplying reagents used in OrganoTherapeutics' organoid workflows.

Broad incumbents

• Cellular Dynamics International (Fujifilm): US-based, Fujifilm-owned provider of iPSC-derived differentiated cell types including neural cells at industrial scale. Broad incumbent with overlapping iPSC-derived cell products for research and drug discovery.
• STEMCELL Technologies: Canada-based developer of specialty reagents, media, and tools for organoid and stem cell research. Broad incumbent supplying the infrastructure (reagents, media, matrices) that enables organoid CROs including OrganoTherapeutics.
• Charles River Laboratories: Large global CRO offering preclinical research services including CNS and neurodegenerative disease models. Broad incumbent that could enter or expand specialized organoid services for Parkinson's research.
• Crown Bioscience: Global preclinical CRO offering in vivo and in vitro services including organoid-based drug screening for oncology and other indications. Comparable as a large-scale preclinical services provider that increasingly incorporates organoid platforms.

Direct peers

• BrainXell: US-based developer of iPSC-derived neural stem cells and neural organoids for CNS drug discovery, with particular focus on Parkinson's disease modeling. Directly comparable specialty organoid CRO/product company.
• Ncardia: Belgium-based iPSC-derived cell technology company offering neural and cardiac cell products and CRO services for drug discovery. Directly comparable to OrganoTherapeutics in iPSC-derived human neural models and preclinical disease modeling services.
• bit.bio: UK-based synthetic biology company providing iPSC-derived human cell products at scale for research and drug discovery. Comparable as an iPSC-derived cell product company targeting pharma/biotech research customers.
• Axol Bioscience: UK-based provider of iPSC-derived neural cells and organoids for neuroscience and drug discovery research. Direct peer in iPSC-derived neural cell products and disease modeling services.

Emerging players

• Priavoid GmbH: German biotech developing all-D-peptide therapeutics for Parkinson's disease, including PRI-101 validated on OrganoTherapeutics' platform. Adjacent emerging player in PD therapeutics rather than competing CRO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=-pbVhFG62to
• LinkedInlinkedin.com/company/organotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrganoTherapeutics